- Trials with a EudraCT protocol (10)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
10 result(s) found for: Sugar phosphate.
Displaying page 1 of 1.
EudraCT Number: 2015-001086-50 | Sponsor Protocol Number: HypoGB2015 | Start Date*: 2015-06-03 | |||||||||||
Sponsor Name:Køge Sygehus | |||||||||||||
Full Title: Treatment of hypoglycemia following gastric bypass surgery | |||||||||||||
Medical condition: Postprandial reactive hypoglycemia in patients with prior Roux-en-Y gastric bypass surgery. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-005547-17 | Sponsor Protocol Number: RHMNUT0048 | Start Date*: 2010-01-28 |
Sponsor Name:Southampton University Hospital NHS Trust | ||
Full Title: Refeeding risks in patients requiring nutrition support. A twin centre double-blind randomised controlled trial of parenteral nutrition support. | ||
Medical condition: Patients who have a non-functioning gastrointestinal tract require artifical intravenous nutrition. This is usally a result recent surgery or sepsis causing a reversible short term paralysis of th... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2019-004610-34 | Sponsor Protocol Number: DexaCup | Start Date*: 2020-06-26 |
Sponsor Name:Rigshospitalet | ||
Full Title: An investigation of postoperative pain, why still in hospital and days alive and out of hospital following transoral robotic surgery for squamous cell carcinoma of unknown primary and obstructive s... | ||
Medical condition: Postoperative pain following transoral robotic surgery | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DK (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-001049-25 | Sponsor Protocol Number: MK8835-017 | Start Date*: 2014-12-16 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Clinical Trial to Evaluate the Efficacy and Safety of the Initial Combination of Ertugliflozin (MK-8835/PF-049... | |||||||||||||
Medical condition: Treatment of type 2 diabetes mellitus (T2DM) with Inadequate Glycemic Control on Diet and Exercise | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) GB (Completed) CZ (Completed) EE (Completed) BG (Completed) HR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-003698-82 | Sponsor Protocol Number: MK8835-005 | Start Date*: 2014-07-09 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: A Phase III, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of the Combination of Ertugliflozin (MK-8835/PF-04971729) with Sitagliptin Compared with Ertugliflozin A... | |||||||||||||
Medical condition: Treatment of type 2 diabetes mellitus (T2DM) and inadequate glycemic control on treatment with metformin. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) CZ (Completed) IT (Completed) GB (Completed) FI (Completed) SK (Completed) BG (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-004622-96 | Sponsor Protocol Number: 0431-260 | Start Date*: 2011-12-23 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. (hereafter referred to as | |||||||||||||
Full Title: A Phase III, Multicenter, Randomized, Double-Blind, Placebo- Controlled Clinical Trial to Study the Safety and Insulin-Sparing Efficacy of the Addition of Sitagliptin in Patients With Type 2 Diabet... | |||||||||||||
Medical condition: Type 2 Diabetes Mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) DE (Completed) IE (Completed) LT (Completed) DK (Completed) HU (Completed) BE (Completed) GB (Completed) IT (Completed) PT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-003100-11 | Sponsor Protocol Number: OSAG 101-BSC-05 | Start Date*: 2006-02-14 |
Sponsor Name:Oncoscience AG | ||
Full Title: Phase III Study on the effectiveness of OSAG 101 (Theraloc) in newly diagnosed intrinsic pontine gliomas of children and adolescents | ||
Medical condition: Newly diagnosed pontine glioma | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: DE (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-000602-22 | Sponsor Protocol Number: B2611002 | Start Date*: 2011-06-29 | |||||||||||
Sponsor Name:Pfizer Inc | |||||||||||||
Full Title: A 12-WEEK, PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, DOSE-RANGING, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ONCE DAILY PF-04991532 AND SITAGLIPTIN IN ADULT PATIENTS ... | |||||||||||||
Medical condition: Type 2 Diabetes Mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Completed) HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-000723-32 | Sponsor Protocol Number: B2611003 | Start Date*: 2011-07-29 | |||||||||||
Sponsor Name:Pfizer Inc | |||||||||||||
Full Title: A 12-WEEK, PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWICE DAILY PF-04991532 AND ONCE DAILY SITAGLIPTIN IN ADU... | |||||||||||||
Medical condition: Type 2 Diabetes Mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Completed) HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-004002-25 | Sponsor Protocol Number: B1621007 | Start Date*: 2012-01-12 | |||||||||||
Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017 | |||||||||||||
Full Title: A PHASE 2, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED, DOSE-RANGING, PARALLEL GROUP STUDY TO EVALUATE SAFETY AND EFFICACY OF PF-04937319 AND SITAGLIPTIN ON GLYCEMIC CONTROL IN ADULT PATIENTS WI... | |||||||||||||
Medical condition: Type 2 Diabetes Mellitus (T2DM) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) SK (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
